<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1120">
  <stage>Registered</stage>
  <submitdate>4/04/2006</submitdate>
  <approvaldate>4/04/2006</approvaldate>
  <nctid>NCT00311376</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>191622-515</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Overactive Bladder</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - botulinum toxin Type A (200U)
Other interventions - botulinum toxin Type A (300U)
Other interventions - Normal Saline (Placebo); botulinum toxin Type A (200U)
Other interventions - Normal Saline (Placebo); botulinum toxin Type A (300U)

Experimental: 1 - botulinum toxin Type A (200U)

Experimental: 2 - botulinum toxin Type A (300U)

Other: 3 - placebo; botulinum toxin Type A (200U)

Other: 4 - placebo; botulinum toxin Type A (300U)


Other interventions: botulinum toxin Type A (200U)
botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at &gt; 12 weeks interval

Other interventions: botulinum toxin Type A (300U)
botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at &gt; 12 weeks interval

Other interventions: Normal Saline (Placebo); botulinum toxin Type A (200U)
Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at &gt; 12 weeks interval

Other interventions: Normal Saline (Placebo); botulinum toxin Type A (300U)
Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at &gt; 12 weeks interval

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Number of Weekly Episodes of Urinary Incontinence - Change from baseline in the weekly frequency of incontinence episodes at Week 6 after the first treatment. Incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).</outcome>
      <timepoint>Baseline, Week 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Maximum Cystometric Capacity (MCC) - Change from baseline in MCC at week 6. MCC represents the maximum volume of urine the bladder holds. A positive number change from baseline represents an improvement (increase) in maximum volume of urine the bladder holds.</outcome>
      <timepoint>Baseline, Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Maximum Detrusor Pressure (MDP) - Change from baseline in MDP during first involuntary detrusor contraction at week 6. MDP represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. The greater the negative number change from baseline, the better the improvement.</outcome>
      <timepoint>Baseline, Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Total Score on Incontinence Quality of Life (I-QOL) Questionnaire - Change from baseline in I-QOL questionnaire total score at Week 6, as completed by the patient. The I-QOL is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). A positive change from baseline represents an improvement</outcome>
      <timepoint>Baseline, Week 6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord
             injury or multiple sclerosis

          -  Inadequate response to anticholinergic medication used to treat overactive bladder</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of evidence of pelvic or urologic abnormality

          -  Previous or current diagnosis of bladder or prostate cancer

          -  Urinary tract infection at time of enrollment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>416</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - Randwick</hospital>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sherbrooke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle (Saale)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A
      in treating overactive bladder in spinal cord injury or multiple sclerosis patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00311376</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>